



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/446,024	12/16/1999	FREDERIC BESEME	105045	1689

7590 01/31/2002

OLIFF & BERRIDGE
PO BOX 19928
ALEXANDRIA, VA 22320

EXAMINER

LEFFERS JR, GERALD G

ART UNIT	PAPER NUMBER
----------	--------------

1636

DATE MAILED: 01/31/2002

14

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/446,024	BESEME ET AL.
	Examiner	Art Unit
	Gerald G Leffers Jr.	1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 09 November 2001.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-14 and 18-38 is/are pending in the application.

4a) Of the above claim(s) 13,14 and 37 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-12,18-36 and 38 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>4, 5</u> .	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Receipt is acknowledged of applicants' preliminary amendment, filed 5/29/01 as Paper No. 9, in which several claims were amended (claims 1-4, 7-14, 18-20) and new claims added (claims 21-38).

Receipt is also acknowledged of applicants' preliminary amendment, filed 11/9/01 as Paper No. 12, in which the specification was amended to include sequence identifiers and in which a new paper copy of the sequence listing, computer readable form and corresponding attorney's statement were submitted.

Election/Restrictions

Applicant's election with traverse of Group I (claims 1-12, 15-20, 21-36, 38), claims drawn toward nucleic acids of a human endogenous retroviral genome and methods of using the same for diagnosis, in Paper No. 9 is acknowledged. The traversal is on the ground(s) that the therapeutic composition of claim 20 has a common technical feature (i.e. nucleic acid sequence) with the nucleic acids and methods of Group I. This is not found persuasive because it is not necessarily true that the nucleic acids used in the methods of Group I will be found in the therapeutic composition of claim 20. Moreover, the therapeutic composition has technical features in addition to just the presence of a nucleic acid derived from a particular source (e.g. pharmaceutically acceptable carriers, synergistic compounds, etc.).

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-14 and 18-38 are pending in this application, with claims 13-14 and 37 withdrawn from consideration as being drawn towards a nonelected invention.

Specification

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Claim Objections

Claims 1-12, 18-36 and 38 are objected to because of the following informalities: many of these claims lack an article (e.g. The, A, etc.) at the beginning of the claim and are grammatically incorrect. Appropriate correction is required.

Claims 33-35 are objected to because of the following informalities: elements a), b), c) recited in the body of these claims are not completely enclosed by parentheses, making it somewhat unclear as to what parts of the dependent claim these elements correspond. It would be remedial to amend the claims to enclose the recited elements completely in parentheses. Appropriate correction is required.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 11 and 28-30 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.

Each of these claims appear to be limited to nucleic acid sequences for which there appears to be no prior art describing a nucleic acid comprising the exact same sequence and for

which a specific and substantial utility has been demonstrated. Therefore, for these sequences there appears to be no well-established utility. Moreover, the prior art does not appear to provide support for any of the asserted utilities for the claimed nucleic acids.

The specification teaches that the claimed sequences were obtained from cDNAs isolated from placenta or from a deduced genomic RNA sequence based upon alignment of several overlapping cDNAs (termed by applicants as HERV-W). This proposed genomic RNA sequence (SEQ ID NO: 11) is described as having several of the characteristics of retroviral genomic RNAs. There is no description of a single genomic clone comprising all of the deduced RNA sequences. It is unclear whether there exists in the human genome a single complete copy of the deduced RNA genome. Several elements of the deduced RNA sequence do appear to be expressed in placental cells and not in several other cell types. The specification teaches that the genomic distribution of the HERV-W sequences throughout the genome is complex, with hundreds of partial sequences scattered across several different chromosomes.

Asserted utilities for the claimed nucleic acids are several, including for example, use of the nucleic acid sequences as markers or probes for several diseases or disorders such as autoimmune disease or unsuccessful pregnancy. All of the asserted utilities are dependent upon the recited sequences actually being correlated with a particular disease or condition. However, the specification provides no convincing evidence that such specific (i.e. correlating to a specific condition) or substantial (i.e. not requiring additional experimentation to identify or confirm) utilities exist for the claimed nucleic acids. For example, the specification bases several of its asserted utilities upon the observation that other human endogenous retroviral nucleic acid sequences have some unspecified degree of correlation to disease or disorders. There is no

Art Unit: 1636

significant correlation, however, between the prior art endogenous retroviral sequences and the instant nucleic acids with regard to specific diseases or disorders, and the specification provides no convincing rational as to why one of skill in the art would expect the claimed nucleic acid sequences to be correlated to the same conditions or diseases as is exhibited by other non-related HERV elements. The specification also asserts that the claimed nucleic acids can be used to diagnose risk of a pathological pregnancy or risk of unsuccessful pregnancy based upon the observation that a few of the sequences comprised within the proposed HERV-W sequence are expressed somewhat specifically in the placenta. However, there is no convincing rational presented in the specification as to why the recited sequences should be associated with a problem pregnancy. For example, there is no comparison of expression of the nucleic acids of the invention in abnormal pregnancies to expression of the same sequences in normal pregnancies.

Given that there is no well-established utility for nucleic acids comprising the recited nucleotide sequences, and that there is no convincing support provided by the specification or prior art for any of the asserted utilities such that the asserted utilities can be considered specific and substantial, one of skill in the art would reasonably conclude that the recited nucleic acid sequences lack specific and substantial utility.

Claims 11 and 28-30 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-12, 15-20, 21-36, 38 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-4 are vague and indefinite in that the metes and bounds of the phrase “nucleic material of the retroviral genomic type” are unclear. The phrase does not appear to be well defined by the specification. For example, how homologous to a reference retroviral nucleotide sequence does a given sequence have to be in order to qualify as a nucleic acid of the “retroviral type”? How much of a nucleic acid derived from a retroviral genome must be present in order for it to be of a “retroviral genomic type”? It would be remedial to amend the claim language to more clearly indicate what is intended by the recited limitation of “nucleic material of the retroviral genomic type”.

Claims 1 and 7 are vague and indefinite in that the metes and bounds of the term “equivalent” when applied to a nucleic acid sequence are unclear. The concept of equivalent protein or nucleic acid sequences does not appear to be well defined in the specification. For example, how homologous to a given reference sequence does a sequence have to be in order to qualify as an “equivalent” sequence to the reference? How much functional similarity for an encoded polypeptide to a reference polypeptide must there be in order for the nucleic or amino acid sequences to qualify as “equivalent”? It would be remedial to amend the claim language to explicitly define what is intended by the term “equivalent”.

Claim 1 is also vague and indefinite in that it is unclear what is intended by the term “reference nucleotide sequence”. This term does not appear to be well defined in the specification. It would be remedial to amend the claim language to clearly indicate what is intended by the recited term.

Claim 2 is vague and indefinite in that the metes and bounds of the phrase “capable of being encoded by at least a functional part of a reference nucleotide sequence” are unclear. Under what conditions is the peptide to be “capable of” being encoded by the recited sequences? Also, what exactly constitutes a “functional part” of a reference sequence? This term does not appear to be clearly defined in the specification.

Claims 3, 12 and 27 are vague and indefinite in that the metes and bounds of the term “fragment” are unclear in light of the claimed invention. What are the limits of a nucleic acid “fragment” in context of the claims? Would a single nucleic acid inserted, as specified in claims 3 and 27, between an LTR and gag gene constitute a “fragment”? From what source is the fragment to be derived? It would be remedial to amend the claim language to clearly indicate what is intended by the recited phrase.

Claim 7 is vague and indefinite in that the metes and bounds of the phrase “partial and complete” are unclear. For example, what constitutes a “complete” nucleic acid sequence according to claim 1? What constitutes a “partial” nucleic acid sequence of one of the recited clones? Would a single nucleotide satisfy this limitation?

Claim 8 is vague and indefinite in that the metes and bounds of the phrase “capable of hybridizing specifically” are unclear? Under what conditions is the hybridization to be

performed? How specific is “specific hybridization”? It would be remedial to amend the claim to include the hybridization conditions and the limits of “specific hybridization”.

Claim 9 is vague and indefinite in that it is not clear what exactly constitutes a “marker” in the context of the claim. Does the term refer to a genetic marker or to some sort of label attached to the probe? Upon reading the specification, it appears the term is intended to specify some sort of label. It would be remedial to amend the claim language accordingly.

Claim 10 is vague and indefinite in that the metes and bounds of the phrase “capable of hybridizing” are unclear? Under what conditions is the hybridization to be performed? It would be remedial to amend the claim to include the hybridization conditions.

Claim 12 is vague and indefinite in that there is no clear and positive prior antecedent basis for the term “nucleotide fragment” in claim 7, upon which claim 12 is dependent.

Claim 18 is vague and indefinite in that the metes and bounds of the term “and/or” are inherently indefinite, making it unclear as to which combinations of limitations are acceptable.

Claim 20 is vague and indefinite in that the claim is drawn towards a non-elected embodiment (i.e. a therapeutic composition). It would be remedial to amend the claim language to delete this limitation.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1636

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-10, 12, 18-36 and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Perron et al (U.S. Patent No. 6,001,987; see the entire document).

The Perron et al patent teaches the identification of sequences derived from a human endogenous retroviral genome and co-infective agent (MSVR-1 and MSVR-2, respectively) and which are associated with multiple sclerosis (MS), a disease with an autoimmune component (e.g. Abstract; column 3, lines 5-30; column 4, lines 15-50). The specification of the '987 patent teaches that the nucleic acids of the invention can be used for detection of a pathogenic and/or infective agent associated with MS (e.g. column 5, lines 10-29). The specification of the '987 patent teaches examples wherein specific MSRV-1 or MSRV-2 sequences are detected in samples (e.g. plasma or blood) obtained from patients having MS (e.g. Example 6).

The attached Sequence Identity search demonstrates that the sequence described by SEQ ID NO: 11 of the instant specification has 78.4% similarity to SEQ ID NO: 57 of the '987 patent. SEQ ID NO: 11 also has 88% similarity to SEQ ID NO: 89 of the '987 patent and 86.4% similarity to SEQ ID NO: 61 of the '987 patent. Figure 1 of the instant specification teaches that

SEQ ID NOS: 1-5, 7-10 are comprised within the proposed genomic RNA sequence described by SEQ ID NO: 11. The search report demonstrates several sequences which have very high identity with SEQ ID NO: 11. For example, from nt 2317 to nt 2438 of SEQ ID NO: 89 of the '987 patent, approximately 100 contiguous monomers, there is ~95% identity to SEQ ID NO: 11 of the instant specification.

Claims 1-9, 11-12, 24-27 and 31-36 are rejected under 35 U.S.C. 102(b) as being anticipated by Pauly or Waterston (Search Report #1, result # 3, Accession No. AC000064; available to the public since 13 November 1996).

As shown in the attached search report, Pauly and Waterston submitted the sequence of a human BAC clone, RG083M05. This sequence was available to the public as of 13 November 1996. Applicants admit in their specification that this genomic clone was available in the art at the time of applicants' invention and that the putative genomic RNA sequence has ~96% identity over its length with the sequence of RG083M05 (e.g. Example 2). The entire nucleotide sequence of RG083M05 can be used as a probe capable of hybridizing to SEQ ID NO: 11. Nucleic acid sequences within the BAC clone can be considered as "markers" for detection.

Conclusion

Claims 1-14, 18-38 are pending. Claims 13-14 and 37 are withdrawn from consideration as being directed towards a nonelected invention. No claims are allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr. whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7939 for regular communications and (703) 305-7939 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Gerald G Leffers Jr.
Examiner
Art Unit 1636

AAZ
ggl
January 28, 2002

DAVID GUZO
PRIMARY EXAMINER


L Number	Hits	Search Text	DB	Time stamp
1	25	beseme-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:11
7	53	blond-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:11
13	203	bouton-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:12
19	119	mandrand-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:12
25	323	mallet-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:12
31	618	perron-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:12
37	1	beseme-\$.in. and blond-\$.in. and bouton-\$.in. and mandrand-\$.in. and mallet-\$.in. and perron-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:12
43	1245	beseme-\$.in. or blond-\$.in. or bouton-\$.in. or mandrand-\$.in. or mallet-\$.in. or perron-\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:13
49	0	(beseme-\$.in. or blond-\$.in. or bouton-\$.in. or mandrand-\$.in. or mallet-\$.in. or perron-\$.in.) and (herv-w)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:13
55	27	(beseme-\$.in. or blond-\$.in. or bouton-\$.in. or mandrand-\$.in. or mallet-\$.in. or perron-\$.in.) and ((herv-\$2) or (endogenous adj4 retrovir\$4))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:19
61	323	((herv-\$2) or (endogenous adj4 retrovir\$4))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:19
67	30	((herv-\$2) or (endogenous adj4 retrovir\$4)).ti.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:19
73	11	((herv-\$2) or (endogenous adj4 retrovir\$4)).clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:20
79	39	((herv-\$2) or (endogenous adj4 retrovir\$4)).ti.) or ((herv-\$2) or (endogenous adj4 retrovir\$4)).clm.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:20
85	35	((herv-\$2) or (endogenous adj4 retrovir\$4)).ti.) or ((herv-\$2) or (endogenous adj4 retrovir\$4)).clm.)) not ((beseme-\$.in. or blond-\$.in. or bouton-\$.in. or mandrand-\$.in. or mallet-\$.in. or perron-\$.in.) and ((herv-\$2) or (endogenous adj4 retrovir\$4)))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/28 08:20

(FILE 'HOME' ENTERED AT 08:47:47 ON 28 JAN 2002)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 08:48:08 ON 28 JAN 2002

L1 60 S (BESEME, ?)/IN,AU
L2 863 S (BLOND, ?)/IN,AU
L3 455 S (MANDRAND, ?)/IN,AU
L4 5300 S (MALLET, ?)/IN,AU
L5 1773 S (PERRON, ?)/IN,AU
L6 8 S L1 AND L2 AND L3 AND L4 AND L5
L7 2 DUPLICATE REMOVE L6 (6 DUPLICATES REMOVED)
L8 8268 S L1 OR L2 OR L3 OR L4 OR L5
L9 40 S L8 AND HERV-W
L10 14 DUPLICATE REMOVE L9 (26 DUPLICATES REMOVED)
L11 13 S L10 NOT L6
L12 3 S L8 AND HERV-H
L13 1 DUPLICATE REMOVE L12 (2 DUPLICATES REMOVED)
L14 3520 S HUMAN (S) ENDOGENOUS (S) RETROVIR?
L15 3497 S L14 NOT (L6 OR L9 OR L12)
L16 260 S L15 AND (PLACENTA OR PREGN?)
L17 8 S L16 AND HERV-H
L18 2 DUPLICATE REMOVE L17 (6 DUPLICATES REMOVED)
L19 14 S L16 AND HERV-W
L20 5 DUPLICATE REMOVE L19 (9 DUPLICATES REMOVED)

GenCore version 4.5
copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on:

August 15, 2001, 11:11:46 ; Search time 20850.3 Seconds

(without alignments)

5624.693 Million cell updates/sec

Title: US-09-446-024-11

Perfect score: 7582

Sequence: 1 caacaatcggtatataacc.....tattaatcttgcatctgcr 7582

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1344157 seqs., 7733874588 residues

Total number of hits satisfying chosen parameters: 2688314

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summariesDatabase : GenEmbl: *
1: gb_ba1: *
2: gb_ba2: *
3: gb_ba3: *
4: gb_in1: *
5: gb_in2: *
6: gb_in3: *
7: gb_om: *
8: gb_ov: *
9: gb_pat1: *
10: gb_pat2: *
11: gb_ph: *
12: gb_p11: *
13: gb_p12: *
14: gb_p13: *
15: gb_p14: *
16: em_ba1: *
17: em_ba2: *
18: em_fun: *
19: em_htg_hum: *
20: em_htg_inv: *
21: em_htg_rod: *
22: em_htg_hum1: *
23: em_htg_hum2: *
24: em_htg_hum3: *
25: em_htg_hum4: *
26: em_htg_hum5: *
27: em_htg_hum6: *
28: em_htg_hum7: *
29: em_htg_hum8: *
30: em_htg_inv1: *
31: em_htg_inv2: *
32: em_htg_other: *
33: em_htg_rod: *
34: em_hum1: *
35: em_hum2: *
36: em_hum3: *
37: em_hum4: *
38: em_hum5: *
39: em_hum6: *
40: em_hum7: *
41: em_in1: *
42: em_in2: *
43: em_in3: *

44: em_ov: *

45: em_pat: *

46: em_ph: *

47: em_pi: *

48: em_ro: *

49: em_sts: *

50: em_sy: *

51: em_un: *

52: em_v1: *

53: gb_sts1: *

54: gb_sts2: *

55: gb_sts3: *

56: gb_sy: *

57: gb_un: *

58: gb_v11: *

59: gb_v12: *

60: gb_htg1: *

61: gb_htg2: *

62: gb_htg3: *

63: gb_htg4: *

64: gb_htg5: *

65: gb_htg6: *

66: gb_htg7: *

67: gb_htg8: *

68: gb_htg9: *

69: gb_htg10: *

70: gb_htg11: *

71: gb_htg12: *

72: gb_htg13: *

73: gb_htg14: *

74: gb_htg15: *

75: gb_htg16: *

76: gb_htg17: *

77: gb_htg18: *

78: gb_htg19: *

79: gb_htg20: *

80: gb_htg21: *

81: gb_htg22: *

82: gb_htg23: *

83: gb_htg24: *

84: gb_htg25: *

85: gb_pr1: *

86: gb_pr2: *

87: gb_pr3: *

88: gb_pr4: *

89: gb_pr5: *

90: gb_pr6: *

91: gb_pr7: *

92: gb_pr8: *

93: gb_pr9: *

94: gb_roi: *

95: gb_rod: *

96: gb_in1: *

97: gb_pr10: *

98: em_ba3: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	7489.6	98.8	7582 9	AX000966 Sequence
2	7489.6	98.8	7582 9	AX027480 Sequence
3	6448	85.0	56093 93	HSAC000064 Human BAC
4	6448	85.0	149194 86	AC007566 Human BAC
5	6336	84.9	10499 9	AX007980 Sequence
6	5824.2	76.8	158053 65	AC018936 Homo sapi
7	5492	72.4	193159 61	AC009727 Homo sapi
8	4302.2	85	AC005187	Homo sapi

HSAC000064 HSAC000064 56093 bp DNA from 7-21-7523 PRI 13-NOV-1996
 Locus Human PAC 5' end sequence from 7-21-7523 commercial
 Definition

ACCESSION
NUMBER
AC000064.1
VERSION
1
KEYWORDS
HTG.
COMMA
SEPARATED
VALUES

ORGANISM *Homosapiens* **Kingdom** Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Eukaryota; **Phylum** Chordata; **Class** Cataphonti; **Order** Primates; **Family** Hominidae; **Genus** Homo

REFERENCE 1 (bases 1 to 38093)
AUTHORS Pawley, A.
:

THE SEQUENCE OF THE SUBJECTS AND THEIR RESULTS
Unpublished (1996)

AUTHORS Waterston, R.

JOURNAL Submitted (13-NOV-1996)

Department of Genetics, University of Wisconsin, Madison, WI 53706

e-mail: sapiens@wustl.edu

NOTICE: This sequence may not represent the entire clone. It may be shorter because we only sequence

neighbouring submissions:

This sequence was finished as follows unless otherwise noted: all regions were double-stranded or sequenced with an alternate chemist; an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

This clone is from the first release of the human BAC library. The library contains cloned DNA from a human male fibroblast cell line 978SK. For references see: Shizuya et al., Proc. Natl. Acad. Sci. 89:8794-8797 (1992); Kim et al., Genomics 34:213-218 (1996). VECTOR: PBELO Selection: chloramphenicol

NEIGHBORING SEQUENCE INFORMATION:
The orientation of this clone is: unknown. Actual start of this
clone is at base position 1 of H_RG083M05; actual end is at 56093
of H_RG083M05

FEATURES source

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 15, 2001, 11:11:46 ; Search time 285.92 Seconds

(without alignments)
5020.135 Million cell updates/sec

Title: US-09-446-024-11

Perfect score: 7582

Sequence: 1 caacaaatccggatataacc.....tattaaatcttgccatctgcr 7582

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 324599 seqs, 9465562 residues

Total number of hits satisfying chosen parameters: 649198

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA:*

1: /cgn2_6/ptodata/2/ina/5A_COMB.seq:*

2: /cgn2_6/ptodata/2/ina/5B_COMB.seq:*

3: /cgn2_6/ptodata/2/ina/6A_COMB.seq:*

4: /cgn2_6/ptodata/2/ina/6B_COMB.seq:*

5: /cgn2_6/ptodata/2/ina/PCUS_COMB.seq:*

6: /cgn2_6/ptodata/2/ina/backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Length	DB	ID	Description
1	1415.8	18.7	2391	3	US-08-691-563C-57	Sequence 57, Appl
2	1059.4	14.1	1577	3	US-08-691-563C-89	Sequence 89, Appl
3	947.8	12.5	1167	3	US-08-691-563C-61	Sequence 61, Appl
4	932.4	12.3	1158	1	US-08-471-724-1	Sequence 1, Appl
5	932.4	12.3	1158	2	US-08-471-724-1	Sequence 2, Appl
6	932.4	12.3	1158	2	US-08-384-137-1	Sequence 1, Appl
7	932.4	12.3	1158	2	US-08-470-0060-1	Sequence 1, Appl
8	932.4	12.3	1158	3	US-08-691-563C-1	Sequence 1, Appl
9	932.4	12.3	1158	4	US-09-200-990-1	Sequence 1, Appl
10	644.4	8.5	2448	3	US-08-691-563C-53	Sequence 53, Appl
11	624.4	8.2	2389	3	US-08-691-563C-52	Sequence 52, Appl
12	589.6	7.8	1196	3	US-08-691-563C-56	Sequence 56, Appl
13	582.2	7.7	741	1	US-08-471-724-9	Sequence 9, Appl
14	582	7.7	741	2	US-08-471-969-9	Sequence 9, Appl
15	582	7.7	741	2	US-08-384-137-9	Sequence 9, Appl
16	582	7.7	741	2	US-08-470-0060-9	Sequence 9, Appl
17	582	7.7	741	3	US-08-691-563C-9	Sequence 9, Appl
18	582	7.7	741	4	US-09-200-990-9	Sequence 8, Appl
19	520.4	6.9	645	1	US-08-471-724-8	Sequence 8, Appl
20	520.4	6.9	645	2	US-08-471-969-8	Sequence 8, Appl
21	520.4	6.9	645	2	US-08-384-137-9	Sequence 8, Appl
22	520.4	6.9	645	2	US-08-470-0060-8	Sequence 8, Appl
23	520.4	6.9	645	3	US-08-691-563C-8	Sequence 8, Appl
24	520.4	6.9	645	4	US-09-200-990-8	Sequence 8, Appl
25	509.8	6.7	542	1	US-08-680-8789-48	Sequence 48, Appl
26	509.8	6.7	542	1	US-08-721-489-2	Sequence 2, Appl
27	432.6	5.7	693	3	US-08-691-563C-88	Sequence 88, Appl

ALIGNMENTS

RESULT: 1
US-08-691-563C-57
Sequence 57, Application US/08691563C
Patent No. 6001987
GENERAL INFORMATION:
APPLICANT: Herve PERON
APPLICANT: Frederic BESEME
APPLICANT: Frederic BEGIN
APPLICANT: Glauzia PARAHOS-BACCALA
APPLICANT: Florence KOMURIAN-PRADEL
APPLICANT: Colette JOIVET
APPLICANT: Bernard MANDRAND
TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR DIAGNOSTIC, PROPHYLATIC AND THERAPEUTIC PURPOSES
NUMBER OF SEQMENTS: 92
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oliff & Berridge
STREET: 700 South Washington Street, Suite 300
CITY: Alexandria
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/691-563C
FILING DATE: 02-AUG-1996
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 38588
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 2391 base Pairs
TYPE: nucleotide
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-691-563C-57

Query Match Best Local Similarity 18.7%; Score 1415.8; DB 3; Length 2391; Pred. No. 0;

